生物制剂与靶向合成改善病情抗风湿药对类风湿关节炎患者新发慢性肾脏病影响的比较
这项多中心队列研究纳入2187例基线eGFR≥60 ml/min/1.73 m2、在日本启动TNF抑制剂、CTLA4-Ig、IL-6受体抑制剂或JAK抑制剂的类风湿关节炎患者,共3068个治疗疗程,随访至11年,275例发生慢性肾脏病。与CTLA4-Ig组相比,TNF抑制剂组慢性肾脏病发生率显著更低(HR 0.67,95%CI 0.46-0.97,P=0.04),JAK抑制剂组显著更高(HR 2.16,95%CI 1.23-3.79,P=0.01);JAK抑制剂组eGFR下降轨迹显著大于CTLA4-Ig组。
要点
- 与CTLA4-Ig相比,TNF抑制剂与新发慢性肾脏病风险降低相关(HR 0.67,95%CI 0.46-0.97,P=0.04)。
- 与CTLA4-Ig相比,JAK抑制剂与新发慢性肾脏病风险升高相关(HR 2.16,95%CI 1.23-3.79,P=0.01)。
- JAK抑制剂组eGFR年下降幅度大于CTLA4-Ig组(-2.29 vs -1.28 ml/min/1.73 m2/年,P<0.001)。
核心结论
- TNF抑制剂的使用与新发慢性肾脏病发生率降低相关,而JAK抑制剂在类风湿关节炎患者中显示对肾脏功能的保护作用较弱。
研究设计与样本
- 多中心队列研究,纳入2187例基线eGFR≥60 ml/min/1.73 m2、在日本启动TNF抑制剂、CTLA4-Ig、IL-6受体抑制剂或JAK抑制剂的类风湿关节炎患者,共3068个治疗疗程,随访至11年。
- 采用多重倾向评分逆概率加权(IPW)校正混杂因素,使用IPW混合效应Cox比例风险模型比较各组慢性肾脏病发生率,并使用线性混合效应模型分析eGFR轨迹。
主要发现
- 随访期间共275例发生慢性肾脏病。
- 与CTLA4-Ig组相比,TNF抑制剂组慢性肾脏病发生率显著更低(HR 0.67,95%CI 0.46-0.97,P=0.04)。
- 与CTLA4-Ig组相比,JAK抑制剂组慢性肾脏病发生率显著更高(HR 2.16,95%CI 1.23-3.79,P=0.01)。
- eGFR年下降幅度在JAK抑制剂组大于CTLA4-Ig组(CTLA4-Ig:-1.28 ml/min/1.73 m2/年,JAK抑制剂:-2.29 ml/min/1.73 m2/年,P<0.001)。
关键数值与推荐
- 纳入标准为基线eGFR≥60 ml/min/1.73 m2的类风湿关节炎患者。
- 主要比较指标为新发慢性肾脏病发生率及eGFR轨迹。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The impact of individual biological/targeted synthetic DMARD (b/tsDMARD) on kidney function in patients with RA remains unclear. This study aimed to determine the comparative effects of b/tsDMARDs on chronic kidney disease (CKD) incidence in patients with RA. METHODS: This multicentre cohort study included patients with RA who had baseline estimated glomerular filtration rate (eGFR) of ≥60 ml/min/1.73 m2 and started a TNF inhibitor (TNFi), cytotoxic T-lymphocyte-associated antigen-4-Ig (CTLA4-Ig), interleukin-6 receptor inhibitor, or Janus kinase inhibitor (JAKi) in Japan. Multiple propensity score-based inverse probability weighting (IPW) was used to adjust confounders. The incidence of CKD was compared among b/tsDMARDs using IPW mixed-effect Cox proportional hazards models and linear mixed-effect models with IPW-examined trajectories of eGFR. RESULTS: Among 2187 patients with 3068 treatment courses and up to 11 years of follow-up, CKD occurred in 275 cases. Compared with the CTLA4-Ig group, the TNFi group had a significantly lower CKD incidence [hazard ratio (HR) 0.67, 95% CI 0.46-0.97, P = 0.04], whereas the JAKi group had a significantly higher incidence (HR 2.16, 95% CI 1.23-3.79, P = 0.01). The trajectory of eGFR was significantly greater in the JAKi group than in the CTLA4-Ig group (CTLA4-Ig: -1.28 ml/min/1.73 m2/year, JAKi: -2.29 ml/min/1.73 m2/year, P < 0.001). CONCLUSIONS: TNFi use was associated with reduced CKD incidence, whereas JAKi showed a less protective association for kidney function in patients with RA.
引用
- Nishimura N, Onishi A, Yamamoto W, et al. Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 39475445. doi:10.1093/rheumatology/keae603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。